$ARIA Company News Six stocks to watch 3:27 p.m. Feb.

New Post Public Reply Private Reply Replies (0) Message Board

Jan 5, 2015 at 10:42 AM

$ARIA Company News

Six stocks to watch 3:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 3:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 9:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 1:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 3:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 4:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 3:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 6:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 3:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com

Benzinga's Top #PreMarket Losers 7:22 a.m. Today - benzinga.com
Is Ariad Pharmaceuticals (ARIA) Stock a Solid Choice Right Now? - Tale of the Tape 8:55 a.m. Jan. 2, 2015 - Zacks.com
ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog 2:35 p.m. Dec. 31, 2014 - Zacks.com
Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More 8:17 a.m. Dec. 30, 2014 - benzinga.com
Ariad inks Iclusig distribution deal for Central and Eastern Europe 7:55 a.m. Dec. 30, 2014 - Seeking Alpha
China Biotech Week In Review: Otsuka Buys Rights To ARIAD's Leukemia Drug 12:30 p.m. Dec. 28, 2014 - Seeking Alpha
Ariad Pharma inks commercialization deal in Asia 7:43 a.m. Dec. 23, 2014 - Seeking Alpha
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve) 9:02 a.m. Dec. 19, 2014 - TheStreet.com
Mid-Afternoon Market Update: Oxford Industries Drops On Downbeat Results; Office Depot Shares Spike Higher 2:59 p.m. Dec. 11, 2014 - benzinga.com
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years 2:52 p.m. Dec. 11, 2014 - TheStreet.com
Mid-Day Market Update: Dow Jumps Over 200 Points; Staples Shares Surge On Confirmation Of Stake By Starboard Value 11:40 a.m. Dec. 11, 2014 - benzinga.com
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action? 9:14 a.m. Dec. 11, 2014 - TheStreet.com
Morning Market Losers 8:57 a.m. Dec. 11, 2014 - benzinga.com
Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers 8:56 a.m. Dec. 11, 2014 - TheStreet.com
Top Analyst Upgrades and Downgrades: ARIAD, FedEx, Genpact, Suncor, Travelers, UPS and More 7:38 a.m. Dec. 11, 2014 - 247WallSt.com
UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak 7:06 a.m. Dec. 11, 2014 - benzinga.com
Long-term follow up data for Iclusig positive 10:54 a.m. Dec. 9, 2014 - Seeking Alpha
ARIAD Reports Follow-up Data from Phase 1, PACE Trials of Ponatinib for T315I Mutation 6:37 a.m. Dec. 9, 2014 - benzinga.com
ARIAD Reports Long-term Safety, Efficacy Data of Ponatinib from Phase 2 Pace Trial: 83% of CP-CML Patients Achieved Response 6:36 a.m. Dec. 8, 2014 - benzinga.com
Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock 7:06 p.m. Dec. 3, 2014 - TheStreet.com

Striking Deals on Street: New Research on State Investors, NCI, Ariad, Under Armour and Meadowbrook 9:20 a.m. Dec. 31, 2014 - PR Newswire - PRF
ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries 7:35 a.m. Dec. 30, 2014 - BusinessWire - BZX
ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference 7:35 a.m. Dec. 22, 2014 - BusinessWire - BZX
Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma 9:15 a.m. Dec. 18, 2014 - PR Newswire - PRF
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial 7:35 a.m. Dec. 8, 2014 - BusinessWire - BZX
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison 8:45 a.m. Nov. 25, 2014 - PR Newswire - PRF
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia 7:35 a.m. Nov. 24, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting 9:44 a.m. Nov. 6, 2014 - BusinessWire - BZX
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress 7:36 a.m. Nov. 5, 2014 - BusinessWire - BZX
ARIAD to Present at the Stifel 2014 Healthcare Conference 7:35 a.m. Nov. 4, 2014 - BusinessWire - BZX
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe 6:35 a.m. Oct. 24, 2014 - BusinessWire - BZX
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind 7:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power 7:45 a.m. Oct. 20, 2014 - PR Newswire - PRF
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results 6:35 a.m. Oct. 15, 2014 - BusinessWire - BZX
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency 6:44 a.m. Oct. 10, 2014 - BusinessWire - BZX
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology 6:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib 6:35 a.m. Oct. 2, 2014 - BusinessWire - BZX
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer 6:35 a.m. Sept. 29, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Ping An's Bold Green Moves Ahead of APEC 2026

By Owen Jenkins Updated Oct 25, 2026 Category News Views 201

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Fluence Energy Hits Legal Snag: Investors Called to Act

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...